Ultra-fractionated Radiotherapy for Rectal Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The rationale of this clinical trial is to assess the feasibility of selective non-operative management for locally advanced rectal cancer using dose-escalated ultra-fractionated short course radiation therapy interdigitated with chemotherapy. We believe delivering short course radiotherapy over a prolonged interval, at escalated doses and with concurrent chemotherapy may be feasible and allow for improved clinical response.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is ultra-fractionated radiotherapy generally safe for humans?
Ultra-fractionated radiotherapy, also known as ultra-hypofractionated radiotherapy, has been studied in prostate and breast cancer treatments and is generally considered safe. Studies have shown that it has acceptable levels of side effects, both in the short term and long term, making it a viable option for patients.12345
How is Ultra-fractionated Radiotherapy for Rectal Cancer different from other treatments?
Ultra-fractionated Radiotherapy for Rectal Cancer is unique because it involves delivering radiation in several small doses multiple times a day, which is different from the traditional approach of fewer, larger doses. This method aims to improve treatment effectiveness and potentially reduce side effects by spreading out the radiation exposure.678910
What data supports the effectiveness of the treatment Ultra-fractionated Radiotherapy for Rectal Cancer?
Who Is on the Research Team?
Nina Sanford, MD
Principal Investigator
UT SOUTHWESTERN medical CENTRE
Are You a Good Fit for This Trial?
Adults with locally advanced rectal cancer who haven't had previous treatment for it. They must have good organ and bone marrow function, no distant nodal or metastatic disease, and a stable health condition without severe psychiatric illness. Participants need to agree to use contraception during the trial.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Radiation
Participants receive dose-escalated hypofractionated adaptive radiotherapy
Chemotherapy
Participants receive FOLFOX or CAPOX chemotherapy interdigitated with radiotherapy
Follow-up
Participants are monitored for safety, effectiveness, and disease progression
What Are the Treatments Tested in This Trial?
Interventions
- Ultrafractionated Radiotherapy for Rectal Cancer
Ultrafractionated Radiotherapy for Rectal Cancer is already approved in United States, China, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Texas Southwestern Medical Center
Lead Sponsor